Results 61 to 70 of about 4,918 (159)

Mild acute pancreatitis with vildagliptin use

Indian Journal of Endocrinology and Metabolism, 2012
Vildagliptin has not been associated with the development of acute pancreatitis in postmarketing reports except one case report from Sydney, Australia.
Ravikant Saraogi, Ritwika Mallik, Sujoy Ghosh   +2 more
doaj   +1 more source

Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study]

Drugs - Real World Outcomes
Background and Objective Vildagliptin sustained release (XR), a formulation that provides vildagliptin 100 mg with a once-daily dose administration, is a recent introduction to manage type 2 diabetes mellitus in India.
Rakesh Sahay, Anil Bhansali, Surendra Kumar Sharma, Rahul Iyer, Amarnath Sugumaran, Senthilnathan Mohanasundaram, Jaideep Gogtay   +6 more
doaj   +1 more source

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Drug Design, Development and Therapy, 2014
Mustafa Cakirca,1 Cumali Karatoprak,1 Mehmet Zorlu,1 Muharrem Kiskac,1 Mustafa Kanat,2 Mehmet Ali Cikrikcioglu,1 Pinar Soysal,3 Mehmet Hursitoglu,4 Ahmet Adil Camli,1 Reha Erkoc,1 Muhammad Abdul-Ghani5 1Internal Medicine Clinic, Faculty of Medicine ...
Cakirca M, Karatoprak C, Zorlu M, Kiskac M, Kanat M, Cikrikcioglu MA, Soysal P, Hursitoglu M, Camli AA, Erkoc R, Abdul-Ghani M   +10 more
doaj  

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study

Diabetes, Metabolic Syndrome and Obesity, 2016
Ahmed AK Hassoun,1 Md Faruque Pathan,2 Rita C Medlej,3,4 Monira Alarouj,5 Inass Shaltout,6 Manoj S Chawla,7 Ditte Knap,8 Julius A Vaz9 1Dubai Diabetes Centre, Dubai, UAE; 2Department of Endocrinology, BIRDEM Hospital, Dhaka, Bangladesh; 3Department of ...
Hassoun AAK, Pathan MF, Medlej RC, Alarouj M, Shaltout I, Chawla MS, Knap D, Vaz JA   +7 more
doaj  

Comparative Effectiveness and Safety of Acarbose and Vildagliptin in Type 2 Diabetes Management: A Real-World Observational Study in an Indian Population

Clinical Diabetology
OBJECTIVE: To evaluate and compare the real-world effectiveness and safety profiles of Acarbose and Vildagliptin in patients with type 2 diabetes (T2D), with an additional focus on their impacts on the gut microbiota.
Shambo Samrat Samajdar, Shatavisa Mukherjee, Rutul Gokalani, Supratik Bhattacharyya, Banshi Saboo, Shashank Joshi   +5 more
doaj   +1 more source

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

Vascular Health and Risk Management, 2008
Nasser MikhailEndocrinology Division, Olive View-UCLA Medical Center, David-Geffen School of Medicine, CA, USAAbstract: Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through ...
Nasser Mikhail
doaj  

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

Vascular Health and Risk Management, 2011
Anja Schweizer1, Sylvie Dejager2, James E Foley3, Wolfgang Kothny31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharma SAS, Rueil-Malmaison, France; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAim: Analyzing safety aspects of a drug ...
Schweizer A, Dejager S, Foley JE, Kothny W   +3 more
doaj  

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

Vascular Health and Risk Management, 2010
James E Foley1, Jens Jordan21Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA; 2Institute for Clinical Pharmacology, Hannover Medical School, Hannover, GermanyAbstract: Various factors may confound how
James E Foley, Jens Jordan
doaj  

Vildagliptin promotes diabetic foot ulcer healing through autophagy modulation

Diabetology & Metabolic Syndrome
The study aimed to investigate the molecular mechanisms underlying the effects of Vildagliptin on the healing of diabetic foot ulcers (DFUs). The research compared patients who received 12 weeks of Vildagliptin treatment to those who did not.
Erik Biros, Venkat Vangaveti, Usman Malabu   +2 more
doaj   +1 more source

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

Vascular Health and Risk Management, 2013
Anja Schweizer,1 James E Foley,2 Wolfgang Kothny,2 Bo Ahrén31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Department of Clinical Sciences, Lund University, Lund, SwedenAbstract: Due to ...
Schweizer A, Foley JE, Kothny W, Ahrén B   +3 more
doaj